Highbridge Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Highbridge Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-77,383	Closed	-$3.03M	–	1766
2017 Q1	$3.03M	Buy	+77,383	New	+$2.46M	0.04%	383
2015 Q2	–	Sell	-18,603	Closed	-$706K	–	1773
2015 Q1	$706K	Sell	18,603 -40,428	-68%	-$1.39M	0.01%	863
2014 Q4	$1.67M	Buy	+59,031	New	+$1.64M	0.02%	516

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Highbridge Capital Management's PTLA Position: Q2 2017 in Review

Highbridge Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 77,383 shares — an estimated $3.03M sold.

Highbridge Capital Management first reported a position in PTLA in Q4 2014 and held it in 3 quarters. The position peaked at $3.03M in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

Highbridge Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 77,383 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $3.03M.
Highbridge Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
Highbridge Capital Management's Portola Pharmaceuticals, Inc. position peaked at $3.03M in Q1 2017.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.